From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cevimeline 3D.png
Systematic (IUPAC) name
Clinical data
Trade names Evoxac
AHFS/Drugs.com monograph
MedlinePlus a608025
Pregnancy cat.
  • C
Legal status
  • Rx only
Routes Oral
Pharmacokinetic data
Protein binding < 20%
CAS number 107233-08-9 YesY
ATC code N07AX03
PubChem CID 83898
DrugBank DB00185
ChemSpider 75707 YesY
KEGG D07667 YesY
Chemical data
Formula C10H17NOS 
Mol. mass 489.565 g/mol
 N (what is this?)  (verify)

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.

Mechanism of action[edit]

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects[edit]

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.[citation needed]

See also[edit]

Salagen - a similar parasympathomimetic medication for dry mouth (Xerostomia)


  1. ^ Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277. 
  2. ^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

External links[edit]